Companies › Alnylam Pharmaceuticals
15 active drug programs in 19 registered trials: 10 Phase 1, 5 Phase 2, 4 Phase 3; Neurology, Cardiovascular, Metabolic and endocrine, Other; next expected readout Dec 2026.
Open in Phaseline: competitors, likelihood bands and readouts Company report
| Drug | Target | Highest phase | Conditions | Next expected readout |
|---|---|---|---|---|
| Vutrisiran Transthyretin mRNA rnai inhibitor | TTR | Phase 3 | Transthyretin Amyloidosis (ATTR) With Cardiomyopathy | Jan 2027 |
| Nucresiran (ALN-TTRSC04) TTR synthesis inhibitor; siRNA targeting TTR mRNA | TTR | Phase 3 | Hereditary Transthyretin-Mediated Amyloidosis With Polyneuropathy; Transthyretin Amyloidosis With Cardiomyopathy | Dec 2027 |
| Zilebesiran Small interfering RNA (siRNA) targeting angiotensinogen (AGT) mRNA | AGT | Phase 3 | High Risk Cardiovascular Disease | Sep 2030 |
| ALN-4324 APOC3 antisense oligonucleotide | – | Phase 2 | Type 2 Diabetes Mellitus (T2DM); Obese or Overweight Healthy Volunteers | May 2027 |
| ALN-6400 unclear - likely RNA interference or RNAi-based therapeutic for VWD and HMB | – | Phase 2 | Von Willebrand Disease (VWD); Hereditary Hemorrhagic Telangiectasia | Jun 2027 |
| ALN-APP siRNA targeting amyloid precursor protein (APP) | APP | Phase 2 | Cerebral Amyloid Angiopathy; Early-Onset Alzheimer Disease | Aug 2027 |
| ALN-AGT01 RVR RNA interference therapeutic targeting AGT; reduces angiotensinogen production | AGT | Phase 2 | Hypertension | Apr 2028 |
| Mivelsiran Antisense oligonucleotide targeting APP mRNA | APP | Phase 2 | Down Syndrome-Associated Alzheimer's Disease (DS-AD) | May 2030 |
| ALN-4285 | – | Phase 1 | Healthy Volunteers | Dec 2026 |
| ALN-2232 RNAi therapeutic targeting APOB | – | Phase 1 | Obesity | Apr 2027 |
| ALN-4915 | – | Phase 1 | Healthy Volunteers | Jul 2027 |
| ALN-BCAT BCAT1 inhibitor | BCAT1 | Phase 1 | Advanced Hepatocellular Carcinoma | Sep 2027 |
| ALN-6222 | – | Phase 1 | Obesity | Dec 2027 |
| ALN-HTT02 HTT-targeting siRNA (RNAi therapeutic targeting huntingtin mRNA) | HTT | Phase 1 | Huntington's Disease | Jul 2028 |
| ALN-5288 apolipoprotein B (APOB) mRNA silencing agent | APOB | Phase 1 | Alzheimer's Disease | Mar 2030 |
| Registry id | Drug | Phase | Conditions | Area | Expected readout |
|---|---|---|---|---|---|
| NCT07295717 | ALN-4285 | Phase 1 | Healthy Volunteers | Other | Dec 2026 |
| NCT04153149 | Vutrisiran | Phase 3 | Transthyretin Amyloidosis (ATTR) With Cardiomyopathy | Cardiovascular | Jan 2027 |
| NCT07463846 | ALN-2232 | Phase 1 | Obesity | Metabolic and endocrine | Apr 2027 |
| NCT07465224 | ALN-4324 | Phase 2 | Type 2 Diabetes Mellitus (T2DM) | Metabolic and endocrine | May 2027 |
| NCT07575308 | ALN-6400 | Phase 2 | Von Willebrand Disease (VWD) | Hematology | Jun 2027 |
| NCT07535606 | ALN-4915 | Phase 1 | Healthy Volunteers | Other | Jul 2027 |
| NCT06393712 | ALN-APP | Phase 2 | Cerebral Amyloid Angiopathy | Neurology | Aug 2027 |
| NCT06845202 | ALN-4324 | Phase 1 | Obese or Overweight Healthy Volunteers | Metabolic and endocrine | Aug 2027 |
| NCT06600321 | ALN-BCAT | Phase 1 | Advanced Hepatocellular Carcinoma | Oncology | Sep 2027 |
| NCT07624071 | ALN-6222 | Phase 1 | Obesity | Metabolic and endocrine | Dec 2027 |
| NCT07223203 | Nucresiran (ALN-TTRSC04) | Phase 3 | Hereditary Transthyretin-Mediated Amyloidosis With Polyneuropathy | Neurology | Dec 2027 |
| NCT06659640 | ALN-6400 | Phase 1 | Hereditary Hemorrhagic Telangiectasia | Cardiovascular | Jan 2028 |
| NCT07553442 | ALN-AGT01 RVR | Phase 2 | Hypertension | Cardiovascular | Apr 2028 |
| NCT06585449 | ALN-HTT02 | Phase 1 | Huntington's Disease | Neurology | Jul 2028 |
| NCT05231785 | ALN-APP | Phase 1 | Early-Onset Alzheimer Disease | Neurology | Jan 2029 |
| NCT07214727 | ALN-5288 | Phase 1 | Alzheimer's Disease | Neurology | Mar 2030 |
| NCT07636811 | Mivelsiran | Phase 2 | Down Syndrome-Associated Alzheimer's Disease (DS-AD) | Neurology | May 2030 |
| NCT07052903 | Nucresiran (ALN-TTRSC04) | Phase 3 | Transthyretin Amyloidosis With Cardiomyopathy | Cardiovascular | May 2030 |
| NCT07181109 | Zilebesiran | Phase 3 | High Risk Cardiovascular Disease | Cardiovascular | Sep 2030 |
Cash and short-term investments of $3.6bn on 2026-09-30; operating cash flow positive
Press releases filed as 8-K in the last year:
Held by 9 of the 39 life-science funds Phaseline follows through their 13F filings. Who holds what.
Roche AstraZeneca Eli Lilly Eisai Acumen Pharmaceuticals JYAMS PET Research & Development Amyloid Solution HTA Nuravax Novo Nordisk
Ionis Pharmaceuticals Biogen Vertex Pharmaceuticals BioMarin Pharmaceutical Arrowhead Pharmaceuticals
Pipelines of the same shape: areas, drug types, target families, stage and cash runway.
Programs group the company's trials by drug; the target and mechanism come from Open Targets and ChEMBL via Open Targets; expected readouts are Phaseline's estimate from the registry's primary completion date. Facts from the registries only; the approval likelihood, shown as a band with its track record, is in the app.